Movement Disorders

As part of NeurologyLive®'s Year in Review 2025, we've compiled the most-listened episodes this year of our biweekly podcast, Mind Moments®.

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Here's some of what is coming soon to NeurologyLive® this week.

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

Here's some of what is coming soon to NeurologyLive® this week.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 21, 2025.

The chief medical officer at Ventyx Biosciences provided commentary on early clinical findings supporting NLRP3 inhibition with VTX3232 as a potential disease-modifying approach for Parkinson disease. [WATCH TIME: 4 minutes]

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

At MDS 2025, the professor of neurology at Northwestern University Feinberg School of Medicine discussed the evolving landscape of disease-modifying clinical trials in Parkinson disease.

At MDS 2025, the chairman and CEO at ABLi Therapeutics discussed phase 2 results of risvodetinib, a highly selective c-Abl inhibitor, in patients with Parkinson disease. [WATCH TIME: 5 minutes]

Liche Zhou, MD, of the department of neurology at Jiang University School of Medicine, provided commentary on new phase 1 data on an iPSC-targeted cell therapy presented at the 2025 MDS Congress.

Jupiter Neurosciences advances Parkinson treatment with FDA clearance for JOTROL's phase 2a trial, showcasing promising safety and bioavailability results.

Catch up on any of the neurology news headlines you may have missed in October 2025, compiled into 1 place by the NeurologyLive® team.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 7, 2025.

A new study presented at the National Society of Genetic Counselors Annual Conference highlights strong interest among individuals at risk for Huntington disease in undergoing modifier gene testing, underscoring the growing role of genetic insights in personal and clinical decision-making.

Brad Racette, MD, FAAN, the Kemper and Ethel Marley Chair for Neurology at Barrow Neurological Institute, discussed his keynote lecture on the neurologic health effects of electric vehicles and the global implications of environmental exposure.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 31, 2025.

A post-hoc analysis study revealed apomorphine sublingual film was efficacious over a long term period across various age ranges, including elders, with Parkinson disease.